Collaborative vaccine clinical trials are now ongoing at the NIH and numerous Cancer Centers throughout the U.S. with vaccines developed in this program. The tumor-associated antigens targeted by these vaccines are (a) carcinoembryonic antigen (CEA), which is overexpressed on the majority of human carcinomas, (b) MUC-1, which is overexpressed on breast and other carcinomas, and (c) prostate-specific antigen (PSA). The genes for these tumor-associated antigens have been placed into two types of recombinant orthopox vectors: recombinant vaccinia and the replication defective avipox virus. Preclinical studies and clinical trials have now demonstrated the optimal use of these vectors in diversified prime and boost vaccine protocols. Immunoassays are currently being developed which detect and characterize T-cell responses to these tumor-associated antigens in vaccinated patients. It has now been shown that vaccinated patients can mount specific immune responses to known epitopes on these tumor antigens; the T cells generated can in turn kill tumor cells expressing these antigens. Agonist epitopes have now been identified for both CEA and PSA. Single amino acid changes in these epitopes have been shown to enhance the generation of cytolytic T-cell responses to both CEA and PSA expressing tumor cells. Studies are ongoing to develop more potent vector-based vaccines. Vectors have now been constructed which express three human costimulatory molecules as transgenes. Preliminary studies have shown that these vectors can be used to markedly enhance the activation of both nanve and memory human T-cell responses. Studies are planned to translate these findings into new clinical vaccine trials.

Agency
National Institute of Health (NIH)
Institute
Division of Basic Sciences - NCI (NCI)
Type
Intramural Research (Z01)
Project #
1Z01BC010425-03
Application #
6763838
Study Section
(LTIB)
Project Start
Project End
Budget Start
Budget End
Support Year
3
Fiscal Year
2002
Total Cost
Indirect Cost
Name
Basic Sciences
Department
Type
DUNS #
City
State
Country
United States
Zip Code
Yang, Sixun; Schlom, Jeffrey (2009) Antigen-presenting cells containing multiple costimulatory molecules promote activation and expansion of human antigen-specific memory CD8+ T cells. Cancer Immunol Immunother 58:503-15
Mostbock, Sven; Lutsiak, M E Christine; Milenic, Diane E et al. (2008) IL-2/anti-IL-2 antibody complex enhances vaccine-mediated antigen-specific CD8(+) T cell responses and increases the ratio of effector/memory CD8(+) T cells to regulatory T cells. J Immunol 180:5118-29
Lutsiak, M E Christine; Tagaya, Yutaka; Adams, Anthony J et al. (2008) Tumor-induced impairment of TCR signaling results in compromised functionality of tumor-infiltrating regulatory T cells. J Immunol 180:5871-81
Schlom, Jeffrey; Arlen, Philip M; Gulley, James L (2007) Cancer vaccines: moving beyond current paradigms. Clin Cancer Res 13:3776-82
Palena, Claudia; Polev, Dmitry E; Tsang, Kwong Y et al. (2007) The human T-box mesodermal transcription factor Brachyury is a candidate target for T-cell-mediated cancer immunotherapy. Clin Cancer Res 13:2471-8
Yokokawa, Junko; Bera, Tapan K; Palena, Claudia et al. (2007) Identification of cytotoxic T-lymphocyte epitope(s) and its agonist epitope(s) of a novel target for vaccine therapy (PAGE4). Int J Cancer 121:595-605
Arlen, Philip M; Gulley, James L; Todd, Nushin et al. (2005) Antiandrogen, vaccine and combination therapy in patients with nonmetastatic hormone refractory prostate cancer. J Urol 174:539-46
Yokokawa, Junko; Palena, Claudia; Arlen, Philip et al. (2005) Identification of novel human CTL epitopes and their agonist epitopes of mesothelin. Clin Cancer Res 11:6342-51
Marshall, John L; Gulley, James L; Arlen, Philip M et al. (2005) Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas. J Clin Oncol 23:720-31
Gulley, James L; Arlen, Philip M; Bastian, Anne et al. (2005) Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clin Cancer Res 11:3353-62

Showing the most recent 10 out of 18 publications